Background
==========

Artemisinin-based combinations (ACT)-the treatment of choice for uncomplicated *Plasmodium falciparum*malaria \[[@B1]\]-are generally safe and well tolerated, but haematologic toxicity remains of potential concern, in particular for treatments containing amodiaquine. Neutropaenia and agranulocytopaenia have been reported in the past with intermittent (weekly) doses of amodiaquine for malaria prophylaxis; the reported rate of serious events (blood dyscrasias) in the UK was 1:2,100 users, with a fatality rate of 1:75,000 \[[@B2]\]. It has been shown that agranulocytosis is unlikely to occur when amodiaquine is used for treatment (as opposed to prophylaxis), but it is not easy to derive information from published information. A meta-analysis of comparative and non-comparative trials of amodiaquine for treating malaria did not show a particular risk of neutropaenia associated with amodiaquine \[[@B3]\]; other systematic reviews have little safety data, especially on haematologic toxicity \[[@B4]\]. Neutropaenia has been reported after administration of treatment doses of amodiaquine, alone or in combination with artesunate \[[@B5]-[@B8]\], and also with artesunate with a dose-dependent risk \[[@B9]\].

Artesunate combined with amodiaquine (AS&AQ) is the second most widely used ACT, adopted as first-line treatment in 18 countries. Over time, AS&AQ has been available in a non-fixed formulation (AS+AQ, as either a loose combination or in blister packs produced by different manufacturers), and more recently, as a fixed-dose, WHO-prequalified, co-formulation (ASAQ).

Although serious adverse events following ACT seem to be uncommon, very few trials compared the haematologic variations between treatments. Two randomized controlled trials (RCT) conducted in sub-Saharan Africa reported no difference in neutropaenia between artesunate-amodiaquine and artemether-lumefantrine \[[@B10],[@B11]\].

Safety in general, and laboratory data in particular, are underreported in malaria trials; risk should be assessed comparatively; databases should be large enough and representative of the spectrum composition of patients and conditions. Limited information can be derived from aggregated data, and individual patient data are best suited for such assessment. The widespread use of these anti-malarial combinations calls for a comprehensive synthesis of available individual patient\'s haematologic data.

Methods
=======

Data on age, parasitaemia, haematologic parameters (white blood cells total counts (WCC), neutrophil and lymphocyte counts, haemoglobin or haematocrit and platelet counts), treatment and treatment outcome were extracted from a database of randomized controlled trials (RCT) including AS&AQ groups conducted in sub-Saharan Africa with 28-day follow-up (26 trials in 16 countries and 33 sites with 11,700 participants). Data were censored when patients dropped out or had recurrent *P. falciparum*. Details on these studies are provided elsewhere \[[@B12]\].

The criteria for selection of the seven RCT were based on the presence of haematologic data (n = 4,502) and comparators including monotherapies: amodiaquine (AQ) or artesunate (AS) alone or other artemisinin combination therapy: artemether-lumefantrine (AL), artesunate plus sulphadoxine/pyrimethamine (AS+SP), dihydroartemisinin-piperaquine (DP) or non-artemisinin containing combinations (AQ+SP) \[[@B5],[@B13]-[@B17]\](Table [1](#T1){ref-type="table"}).

###### 

Number of patients recruited by treatment group and study

  RCT                      Location      Reference    ACT    Mono-therapy   non-ACT   Total                     
  ------------------------ ------------- ------------ ------ -------------- --------- ------- ----- ----- ----- ------
  ACT vs monotherapy       Multicentre   \[[@B5]\]    306                                     307               613
                           Rwanda        \[[@B17]\]   158                                     150               308
                                                                                                                
                           Mali          \[[@B13]\]   252                             249           252         753
  ACT vs ACT and non-ACT   Uganda        \[[@B14]\]   242    217                                          269   728
                           Rwanda        \[[@B15]\]   252                   251                           258   761
                           Multicentre   \[[@B16]\]   626    311                                                937
                           Zanzibar      \[[@B10]\]   202    200                                                402
                                                                                                                
  Total                                               2038   728            251       249     457   252   527   4502

Analysis involved 4,502 patients: 10,677 records in 3,829 patients at various time points for WCC; 8,232 records in 3,069 patients for neutrophils; 12,888 records in 4,276 patients for haemoglobin; and 3,514 records in 1,419 patients for platelets.

Treatments
----------

### AS&AQ treatment regimens

AS&AQ products were either loose (AS+AQ) or fixed-dose co-formulations (ASAQ). The loose AS+AQ was dosed based on body weight, while the co-formulated ASAQ was based on age and weight range.

The proportion of patients treated with AS&AQ was 45% (2,038/4,502) of which 31% (624/2,038) were treated with a fixed-dose ASAQ combination (Coarsucam™, Winthrop), and 69% (1,412/2,038) were treated with loose combinations: in Gabon, Kenya and Uganda was AS (Arsumax™ 50 mg, Sanofi) and AQ (Camoquine™ 200 mg, Parke-Davis); in Zanzibar: AS (Plasmotrim™ 100 mg, Mepha) and AQ (Flavoquin™, 153 mg, Roussel); in Rwanda (Arsumax™, Sanofi \[[@B15]\]), and AQ and AS (Dafra Pharma \[[@B17]\]).

The loose combination target dose was AS 12 mg/kg over three days and AQ 30 mg/kg over 3 days, except in Uganda where AQ was given at 25 mg/kg (10 mg/kg on Days 0 and 1 then 5 mg/kg on Day 2). The fixed-dose combinations of ASAQ (Coarsucam™, Winthrop) were available as two-and three-strength products given by age. The fixed-dose combination was given either once or twice a day. For the two-strength fixed-dose combination ASAQ (paediatric AS 25 mg+AQ 67.5; adult AS 100 mg+AQ 270 mg, dose ratio = 2.7), the dosing categories were: (i) 0-1 months: 1/2 paediatric; (ii) 2-11 months: 1 paediatric; (iii) 1-6 years: 2 paediatric; (iv) 7-13 years: 1 adult; and (v) ≥ 14 years: 2 adults. For the three-strength ASAQ, age- and weight-based doses were administered once-a-day for three days: one tablet/day for children up to 13 years of age (≤ 35 kg) or two tablets/day for adolescents aged 14 years and above and adults (≥ 36 kg). Doses available were: infants (two to 11 months) received AQ 25 mg/AS 67.5 mg; young children (one to 4 years) received AQ 50 mg/AS 135 mg; children (six to 13 years) received one tablet/day of AQ 100 mg/AS 270 mg, and adults (14 years or more) received two tablets (AQ 100 mg/AS 270 mg) per day.

### Other forms of ACT

Patients treated with other forms of ACT accounted for 27% (1,228/4,502) of the total: 728 with AL (20 mg artemether/120 mg lumefantrine given according to weight as one (5-14 kg), two (15-24 kg), three (25-34 kg), and four 4 (≥ 35 kg) tablets given twice daily for three days); 251 with DP (around 2.3 mg/kg/day dihydroartemisinin and 18.4 mg/kg for three days); and 249 with AS+SP (AS 4 mg/kg/day; SP 25 mg/kg of sulphadoxine and 1.25 mg/kg/of pyrimethamine administered in a co-formulated tablet (SP) as a single dose).

### Non-ACT combinations

Patients treated with a non-artemisinin containing combination accounted for 12% (527/4,502): AQ+SP (AQ 10 mg/kg/day for three days and SP 25 mg/kg of sulphadoxine and 1.25 mg/kg/of pyrimethamine administered in a co-formulated tablet (SP) as a single dose).

### Monotherapies

AQ only (10% of patients) was given at 10 mg/kg/day for three days; AS only (6% of patients) was given at a total dose of 12 mg/kg over five days.

Haematology
-----------

The grading of all paediatric haematological values was derived from international standards \[[@B18]-[@B20]\].

Leucopaenia was defined as white blood cell counts (WCC) \< 3 × 10^9^/L; mild/moderate was 3 × 10^9^/L to 2 × 10^9^/L, and severe/very severe leucopaenia was \< 2 × 10^9^/L (grade 3: 1.9 × 10^9^/L to 1 × 10^9^/L and 4: \< 1 × 10^9^/L).

Neutropaenia was defined as neutrophil counts \< 1.20 × 10^9^/L; mild/moderate neutropaenia ranged from 1.19-0.40 × 10^9^/L (grade 1: 1.19 × 10^9^/L to 0.75 × 10^9^/L and 2: 0.74 × 10^9^/L to 0.40 × 10^9^/L), and severe/very severe neutropaenia was \< 0.40 × 10^9^/L (grade 3: 0.39 × 10^9^/L to 0.25 × 10^9^/L and 4: \< 0.25 × 10^9^/L).

For anaemia the cut off was set at haematocrit \< 30% or haemoglobin \< 10 g/dL and was categorized as: mild/moderate from 9.9-8.0 g/dL of haemoglobin (grade 1: 9.9 g/dl to 9.0 g/dL and 2: 8.9 g/dL to 8 g/dL), and severe/very severe \< 8 g/dL of haemoglobin (grade 3: 8 g/dL to 5 g/dL and 4: \< 5 g/dL).

Thrombocytopaenia was defined as platelets count \< 150 × 10^9^/L; mild/moderate ranged 150-50 × 10^9^/L (grade 1: 149 × 10^9^/L to 75 × 10^9^/L and 2: 74 × 10^9^/L to 50 × 10^9^/L), and severe/very severe thrombocytopaenia \< 50 × 10^9^/L (grade 3: 49 × 10^9^/L to 20 × 10^9^/L and 4: \< 25 × 10^9^/L).

Recovery from an abnormal condition was defined for leucopaenia as WCC becoming ≥3 × 10^9^/L, for neutropaenia as ≥1.2 × 10^9^/L, for anaemia as haematocrit becoming ≥30% or haemoglobin ≥10 g/dL, for thrombocytopaenia as platelets ≥150 × 10^9^/L.

A haematological adverse event (AE) was defined as the occurrence of an abnormal value (grade 1 or more, as defined above) after treatment start independent of the pre-treatment value. In this analysis, all visits were considered, thus a subject could have multiple AEs.

A treatment-emergent AE (TEAE) expresses the worsening of the condition-i.e. any occurrence of an abnormal value at any follow-up visit (days 7 through 28) as compared to baseline in patients who either had a normal condition pre-treatment or an abnormal value that was of lower grade than post-treatment. Drug-event relationship could not be attributed in the present analysis.

Statistical analysis
--------------------

Haematologic changes were analysed between Days 0-7, 0-14, and 0-28 using t-student paired analysis and presented as relative difference (Day 0 as the reference). In each RCT, the patients\' paired differences were compared between treatment groups using the Mann-Whitney rank test. Categorical data were compared using a chi-square test or a Fischer exact test or a Mantel-Haenszel chi-square test stratified by site and the comparison presented by odds ratio (OR), as appropriate.

During the 28-day follow-up, the timing of post-treatment haematologic assessments varied across studies (Table [2](#T2){ref-type="table"}), therefore an adjustment for time (day of observation) was included in the multivariate analysis. All available haematologic values for every patient were considered. A random intercept for each individual was included when the Lagrange multiplier (LM) test \[[@B21]\] was significant for heterogeneity in multivariate logistic regression. These multivariate analyses assessed the risks for leucopaenia, neutropaenia, anaemia, and thrombocytopaenia (analysed as binary variables) during follow-up. The adjusted risks (AOR) of the above conditions were assessed over time (continuous, in days), according to the patients\' age (continuous, in years), parasitaemia (continuous, in parasites/μL, log-transformed), parasitological reappearance (or treatment outcome, including recrudescence and re-infections; binary, at the exact day of occurrence) along with the interaction of age and parasitaemia, as well as the potential effects of the various treatments in each RCT.

###### 

Follow-up timing per study and haematologic parameters

  Location       Reference    N     White blood cell counts (WCC)   Neutrophils             Haemoglobin             Platelets
  -------------- ------------ ----- ------------------------------- ----------------------- ----------------------- -------------
  Multi-centre   \[[@B5]\]    613   D0                                                      D0, D28                 
  Multi-centre   \[[@B16]\]   937   D0, D7, D28                     D0, D7, D28             D0, D28                 
  Mali           \[[@B13]\]   753   D0, D7, D14, D28                                        D0, D7, D14, D28        D0, D7, D14
  Rwanda         \[[@B17]\]   308                                                           D0, D14, D28            
  Rwanda         \[[@B15]\]   761   D0, D14                         D0, D14                 D0, D14                 
  Uganda         \[[@B14]\]   728   D0, D14                         D0, D14                 D0, D14                 D0, D14
  Zanzibar       \[[@B10]\]   402   D0, D7, D14, D21, D28           D0, D7, D14, D21, D28   D0, D7, D14, D21, D28   

Legend: *D*day

For relative differences, confidence intervals (CI) were calculated using the normal distribution. All CIs were calculated at 95% (95%CI) and comparisons considered significant when *p*\< 0.05. Data were analysed using Stata v10 (Stata Corp.).

Ethical issues
--------------

All the studies had been approved by the relevant ethics and institution review committees \[[@B5],[@B10],[@B13]-[@B17]\].

Results
=======

The main baseline characteristics of the patients enrolled are displayed in Table [3](#T3){ref-type="table"}. Seventy-two percent (72%, range 32-100%) were children under five years of age from 13 sites in nine countries. The geometric mean pre-treatment parasitaemia was 18,425 overall and ranged from 9,203 to 30,988 parasites/μL, by site. At presentation, leucopaenia and neutropaenia were infrequent (3% and 6% respectively), while thrombocytopaenia and anaemia were found in 32% and 49% of subjects (Table [4](#T4){ref-type="table"}).

###### 

Age and parasitaemia on admission by site

                       N           Parasitaemia (μ/L)   Age (year)                                            
  -------------------- ----------- -------------------- -------------------------- ------------ ------------- -------------
  **Site**             **total**   **geometric mean**   **Under five years old**   **median**   **minimum**   **maximum**
                                                                                                              
  Cameroon             166         24627                44%                        6.2          1.0           65.0
  Gabon                216         22597                42%                        5.4          1.3           10.8
  Kenya                397         30988                80%                        2.0          .5            11.0
  Madagascar           178         9203                 32%                        7.5          1.4           53.1
  Mali-Bancouna        201         22386                54%                        4.7          .9            24.3
  Mali-Bougoula        753         15468                91%                        2.5          .6            13.7
  Rwanda-kicukiro      313         27938                99%                        3.0          .6            5.0
  Rwanda-mashesha      391         18462                99%                        3.0          .5            5.0
  Rwanda-rukara        365         33615                100%                       2.0          .5            4.9
  Senegal              392         19142                50%                        5.0          .9            64.0
  Uganda-Kampala       728         10552                37%                        6.1          1.1           11.5
  Zanzibar-Kivunge     297         16500                97%                        2.5          .5            6.5
  Zanzibar-Micheweni   105         16777                99%                        2.1          .5            5.0
                                                                                                              
  Total                4502        18425                72%                        3.4          .5            65.0

###### 

Haematology on admission by site

                       WCC(\*10^9^/L)   Neutrophils(\*10^9^/L)   Haemoglobin (g/dL)   Platelets(\*10^9^/L)                                                                                                                                                                     
  -------------------- ---------------- ------------------------ -------------------- ---------------------- ------------------ ------- ---------- -------- ------- ------------------- ------- ---------- -------- ------- -------------- ------- ---------- -------- ------- -------------------------
  **Site**             **N**            **mean**                 **SD**               **n**                  **Leuco-poenia**   **N**   **mean**   **SD**   **n**   **Neutro-paenia**   **N**   **Mean**   **SD**   **n**   **Anae-mia**   **N**   **mean**   **SD**   **n**   **Throm-bocyto-paenia**
                                                                                                                                                                                                                                                                               
  Cameroon             166              7.5                      1.7                  0                      0%                 165     4.0        1.4      3       2%                  166     12.1       1.4      153     8%                                                 
  Gabon                216              7.8                      3.0                  2                      1%                 207     3.7        2.4      16      8%                                                                                                         
  Kenya                41               9.6                      3.7                  0                      0%                 41      6.2        3.0      0       0%                  397     9.3        2.0      155     61%                                                
  Madagascar           178              7.1                      3.0                  0                      0%                 167     4.6        2.7      1       1%                  178     11.5       2.3      145     19%                                                
  Mali-Bancouna        201              9.4                      3.7                  1                      0%                 194     6.2        3.1      1       1%                  200     9.9        1.6      99      51%                                                
  Mali-Bougoula        752              10.4                     4.4                  4                      1%                                                                         752     10.2       1.8      424     44%            697     180        93       264     38%
  Rwanda-kicukiro      222              6.7                      2.6                  5                      2%                 222     3.7        2.0      10      5%                  312     10.8       2.0      222     29%                                                
  Rwanda-mashesha      269              5.4                      1.7                  0                      0%                 269     3.0        1.3      5       2%                  391     10.1       1.4      232     41%                                                
  Rwanda-rukara        270              4.0                      1.6                  80                     30%                270     1.8        1.0      80      30%                 365     10.3       1.8      242     34%                                                
  Senegal              392              9.3                      4.5                  2                      1%                 392     5.3        3.2      6       2%                  392     10.1       2.4      209     47%                                                
  Uganda-Kampala       721              7.6                      3.6                  8                      1%                 714     4.3        2.5      26      4%                  728     11.6       1.3      646     11%            717     210        86       186     26%
  Zanzibar-Kivunge     297              6.2                      3.1                  18                     6%                 297     3.5        2.3      22      7%                  297     8.8        1.5      66      78%                                                
  Zanzibar-Micheweni   105              6.4                      1.5                  0                      0%                 105     3.0        1.2      0       0%                  105     8.1        1.5      14      87%                                                
                                                                                                                                                                                                                                                                               
  Total                3830             7.8                      3.9                  120                    3%                 3043    4.0        2.6      170     6%                  4283    10.3       2.0      2607    39%            1414    195        90       450     32%

Frequency of events
-------------------

During follow-up (any time, all observations), abnormal values occurred in 2% (224/10,677) for leucopaenia, 8% (621/8,232) for neutropaenia, 40% (5,102/12,888) for anaemia, 19% (685/3,514) for thrombocytopaenia.

Of all the above events, the proportion of those that were severe (grade 3 and 4) was 8% (19/224) for leucopaenia, 3% (18/621) for neutropaenia, 28% (1,412/5,102) for anaemia, and 15% (100/685) for thrombocytopaenia.

Overall, the proportion of patients with severe leucopaenia was lower on AS&AQ than other treatments (*p*= 0.023 stratified by site, accounted for by a higher frequency with AL in Zanzibar) while no difference was detected for severe neutropaenia, severe anaemia, and severe thrombocytopaenia (*p*= 0.804, *p*= 0.800, *p*= 0.470, respectively, stratified by site).

Haematological treatment emergent adverse events (TEAEs)
--------------------------------------------------------

The occurrence of TEAEs for neutropaenia, anaemia and thrombocytopaenia could be calculated for 1192, 2063 and 1375 patients respectively who had both baseline and follow-up values (through Day 28 for neutropaenia and anaemia, and Day 14 for thrombocytopaenia) (Table [5](#T5){ref-type="table"}). In those treated with AS&AQ, the overall incidence of TEAEs was 11%, 20% and 6%, respectively.

###### 

Post-treatment haematologic adverse event (AE), treatment emergent AEs (TEAE), between Day 0 and Day 28

  Condition           Treatment           Normal on admission   TEAE (n)   AE (n)   TEAE   AE                 
  ------------------- ------------------- --------------------- ---------- -------- ------ ----- ------ ----- -----
  Neutropaenia        AS&AQ               1350                  95%        144      1309   169   1323   11%   13%
                      Other artemisinin   919                   95%        113      944    130   951    12%   14%
                      Non-artemisinin     602                   92%        63       536    80    538    12%   15%
                                                                                                              
  Anaemia             AS&AQ               1141                  59%        343      1750   693   1751   20%   40%
                      Other artemisinin   876                   59%        328      1462   650   1462   22%   44%
                      Non-artemisinin     590                   68%        29       717    82    718    4%    11%
                                                                                                              
  Thrombocytopaenia   AS&AQ               343                   73%        28       463    39    463    6%    8%
                      Other artemisinin   436                   64%        44       672    68    672    7%    10%

No difference was observed for neutropaenia between AS&AQ compared to other artemisinin treatments (*p*= 0.475) or non-artemisinin treatments (*p*= 0.642), and for thrombocytopaenia compared to other artemisinin treatments (*p*= 0.734). In contrast with the incidence of TEAE for anaemia that was higher in AS&AQ or other artemisinin groups compared to non-artemisinin treatments (*p*= 0.001, for both comparisons).

Descriptive paired analysis (baseline *vs*follow-up)
----------------------------------------------------

### Single-agent comparators

#### Amodiaquine (AQ) mono-therapy (Additional file [1](#S1){ref-type="supplementary-material"})

Two RCTs comparing AS&AQ (n = 464) to AQ alone (n = 457) conducted at five sites \[[@B5],[@B17]\] showed no increased risk when adding AS to AQ. There was:

i\. no significant variation in WCC through Day 28 in both groups, and no difference in variations between AS&AQ and AQ (*p*= 0.882). In each group one patient was leucopaenic on admission and recovered; one in the AQ group became leucopaenic and none in the AS&AQ.

ii\. a significant decrease in neutrophils by Day 7 and 14 (-17% and -37%, no data on Day 28) for AS&AQ and on Day 7 for AQ alone (-21%), but no difference between the two groups; there was one neutropaenic patient in the AQ group who recovered and none in the AS&AQ group. Only one patient from the AS&AQ group became neutropaenic.

iii\. a significant increase in haemoglobin in both groups on Days 14 and 28 (final gain 13% and 10%, respectively) with no significant difference between the two groups. The proportion of patients recovering from anaemia by Day 28 was higher with AQ (100%, 19/19) compared to AS+AQ (80%, 24/30, *p*= 0.037). The proportions of patients becoming anaemic were not different between AQ (6%, 3/49) and AS&AQ (2%, 1/48, *p*= 0.385).

#### Artesunate (AS) mono-therapy (Additional file [1](#S1){ref-type="supplementary-material"})

One RCT in Bougoula, Mali \[[@B13]\] comparing AS+AQ (n = 252) to AS (n = 252) showed no increased risk (and a lower risk of anaemia) when adding AQ to AS. There was:

i\. a significant decrease in WCC in both groups without difference between groups through Day 28; there was no leucopaenic patient in both groups during the follow-up.

ii\. an increase in platelets in both groups without difference between the two groups; 92% (11/12) in the AS+AQ, and 75% (3/4) of the patients in the AS group recovered (*p*= 0.802); 15% (4/27) and 40% (2/5), respectively became thrombocytopaenic (*p*= 0.291).

iii\. a significant transient decrease in haemoglobin by Day 7 with AS+AQ and AS alike; by Day 28, the gain in haemoglobin was greater in patients treated with AS+AQ (+10%, 95%CI 7%-13%) than AS alone (+7%, 95%CI 3%-7%, *p*= 0.031). The proportion of patients recovering from anaemia was slightly higher in AS+AQ (64%, 62/97) but not significantly different from AS (55%, 51/93, *p*= 0.203). The risk of becoming anaemic was higher with AS alone (15%, 18/120) than AS+AQ (7%, 9/138, OR 2.53, 1.09-5.87, *p*= 0.026).

ACT comparators
---------------

### Artesunate plus sulphadoxine/pyrimethamine (AS+SP) (Additional file [1](#S1){ref-type="supplementary-material"})

In Mali \[[@B13]\], AS+AQ (n = 252) was compared to AS+SP (n = 249). No difference in WCC and platelets changes was detected between the two groups during follow-up. There was a significant transient decline in haemoglobin by Day 7, and an increase in both groups through Day 28. The proportions of patients recovering from anaemia by Day 28 in AS&AQ (64%, 62/97) compared to AS+SP (62%, 67/108) and becoming anaemic in AS&AQ (7%, 9/138) compared to AS+SP (9%, 11/128) groups were not different (*p*= 0.781 and *p*= 0.522, respectively, for both comparisons).

### Artemether-lumefantrine (AL) combination (Additional file [1](#S1){ref-type="supplementary-material"})

Two RCTs comparing AS&AQ (n = 1070) to AL (n = 762) in seven sites \[[@B10],[@B16]\] showed:

i\. no change in WCC through Day 28 with AL and a significant decrease with AS&AQ on Days 14 and 28 which was significantly greater than AL on Day 28 (-7%, 95%CI -4% to -10% *vs*0%, 95%CI -5%-4%, *p*= 0.017); however, Day 28 WCC were not different between the two groups (7.5 × 10^9^/L and 7.4 × 10^9^/L, *p*= 0.402). The proportion of patients recovering from leucopaenia on admission was not different (AS&AQ = 100%, 10/10, AL = 90%, 9/10). In AS&AQ \< 1% (2/753), and 1% (5/461) of the patients in AL group became leucopaenic (*p*= 0.092).

ii\. a significant decrease in neutrophil counts with both drugs at each time point (Days 7, 14 and 28) which was significantly greater with AS&AQ than AL on Days 14 and 28 (Day 28 variations were -35%, 95%CI -30%-39% with AS&AQ *vs*-28%, 95%CI -22% to -34% with AL, *p*= 0.005); however, Day 28 neutrophil counts were not different (3.1 and 3.0, *p*= 0.861). The proportion of patients recovering from pre-treatment neutropaenia was similar in the two groups (AS&AQ = 89%, 17/19, AL = 85%, 11/13), as well as the proportion of patients becoming neutropaenic (6%, 44/718 and 6%, 27/442, respectively, *p*= 0.989).

iii\. increased lymphocyte counts by over 40% in both the AS&AQ and AL group; no difference in variations was detected between the two groups (for all comparisons).

iv\. by Day 7, a more marked decrease in haemoglobin in the AS&AQ compared to the AL group (*p*= 0.001), and a smaller increase by Day 14 (*p*= 0.049), but by Day 28 no significant difference in haemoglobin levels and the proportions of patients recovering from anaemia (54%, 190/353 and 56%, 138/246, *p*= 0.582, respectively) or becoming anaemic (10%, 39/409 and 8% 19/225, *p*= 0.648, respectively).

v\. a significant increase in platelet counts of about 90% was observed in both groups. All patients recovered in both groups with no patients developing thrombocytopaenia.

### Dihydroartemisinin-piperaquine (DP) (Additional file [1](#S1){ref-type="supplementary-material"})

One RCT in Rwanda \[[@B15]\] comparing AS+AQ (n = 252) to DP (n = 252) provided for haematologic data on admission and Day 14.

i\. WCC decreased significantly in the DP group but not in the AS+AQ group, but the difference between the two groups was statistically non-significant (*p*= 0.24). The proportion of patients recovering from leucopaenia was higher in the AS+AQ (65%, 22/34) than in the DP group (37%, 14/37, *p*= 0.051). However by Day 14, the prevalence rates of leucopaenic patients were not different between groups (8%, 19/247; 9%, 23/248, respectively, *p*= 0.528).

ii\. the prevalence of neutropaenia on admission was 15% (38/252) in the AS+AQ group and 10% (24/251) in the DP group (*p*= 0.060); at Day 14 the prevalence rates were also not different in the AS+AQ group (15%, 37/247) compared to the DP group (10%, 24/248, *p*= 0.073). A significant decrease in neutrophils was observed in both groups. No difference was found between the two groups in the fall in neutrophil counts (*p*= 0.800) or the proportions of patients recovering (*p*= 0.720).

iii\. Patients on AS+AQ had a faster haemoglobin recovery (+10%, 95%CI 7%-13%) by Day 14 than those treated with DP (+6%, 95%CI 3%-9%, *p*= 0.040). The proportion of patients recovering from anaemia was not different between the two groups (*p*= 0.45), but the risk of becoming anaemic with DP (9%, 14/164) was higher (but not significantly different) than with AS+AQ (4%, 6/160, OR 2.40, 95%CI 0.90-6.40, *p*= 0.073).

Non-artemisinin containing comparators
--------------------------------------

### Amodiaquine plus sulphadoxine/pyrimethamine (AQ+SP) (Additional file [1](#S1){ref-type="supplementary-material"})

AS+AQ (n = 494) was compared to AQ+SP (n = 527) in Rwanda and Uganda \[[@B14],[@B15]\] where data were only available on admission and on Day 14. By day 14, WCC slightly decreased with a significant decrease of neutrophils in both groups; haemoglobin and platelets significantly increased in both groups. No difference was detected between treatment groups for all haematologic parameters studied (WCC, neutrophils, platelets).

Adjusted risks and trends
-------------------------

Large inter-individual differences in haematologic outcomes were detected (*p*= 0.001, LM test) requiring the use of random effects. All the following analysis used multivariate logistic regression with random intercept on individuals including all potential risk factors. During the drug-free, post-treatment follow-up, it was found that:

i\. the risk of leucopaenia decreased (AOR 0.96, 95%CI 0.94-0.98, *p*= 0.001), and was lower in older patients (AOR 0.92, 95%CI 0.86-0.98, *p*= 0.013) and higher in patients with higher baseline parasitaemia (AOR 1.80, 95%CI 1.21-2.69, *p*= 0.001). No difference was detected between AS&AQ and comparator treatments (AL, *p*= 0.09; AS, *p*= 0.18; AS+SP, *p*= 0.94; AQ+SP, *p*= 0.63) and treatment outcome (success or parasitological reappearance) (*p*= 0.11). The risk of severe (grade 3 and 4) leucopaenia was lower in older patients (*p*= 0.031) and higher in patients treated from AL (*p*= 0.031, all cases occurring in Zanzibar) compared to AS&AQ.

ii\. the risk of neutropaenia increased (AOR 1.03, 95%CI 1.02-1.04, *p*= 0.001); older patients were at lower risks (AOR 0.92, 95%CI 0.90-0.95, *p*= 0.001). No difference was detected between AS&AQ and either AQ (*p*= 0.16), AL (*p*= 0.56), AQ+SP (*p*= 0.98), or DP (*p*= 0.08), or with respect to treatment outcome (*p*= 0.67) or baseline parasitaemia (*p*= 0.56). No risk of severe neutropaenia (grade 3 and 4) was detected.

iii\. the risk of anaemia decreased (AOR 0.91, 95%CI 0.90-0.92, *p*= 0.001); patients with higher baseline parasitaemia (AOR 1.53, 95%CI 1.30-1.80, *p*= 0.001) and those experiencing recurrent parasitaemia (AOR 1.98, 95%CI 1.35-2.92, *p*= 0.001) were at higher risk, while older patients were at lower risk (AOR 0.67, 95%CI 0.64-0.70, *p*= 0.001). No difference was detected between AS&AQ and either AL (*p*= 0.67), AS + SP (*p*= 0.21), DP (*p*= 0.69), AQ+SP (*p*= 0.22), AQ (*p*= 0.48), or AS (*p*= 0.08). No risk of severe anaemia (grade 3 and 4) was detected.

iv\. the risk of thrombocytopaenia decreased (AOR 0.88, 95%CI 0.87-0.90, *p*= 0.001); older patients (AOR 0.92, 95%CI 0.88-0.96, *p*= 0.001) were at lower risks compared to younger patients; patients with higher baseline parasitaemia (AOR 1.46, 95%CI 1.25-1.70, *p*= 0.001), treated in Uganda with AL (AOR 1.77, 95%CI 1.03-3.04, *p*= 0.040) or AQ+SP (AOR 1.95, 95%CI 1.15-3.32, *p*= 0.013) were at higher risks for thrombocytopaenia by Day 14. In Mali, the risks of patients treated with AS (*p*= 0.64) or AS+SP (*p*= 0.47) were not significantly different from AS&AQ. Patients with a parasitological recurrence were at higher risks for thrombocytopaenia (AOR 3.55, 95%CI 1.29-9.79, *p*= 0.014). There were no data for AQ and DP. Similarly, the risk of severe thrombocytopaenia dropped significantly during follow-up (*p*= 0.025); younger patients (*p*= 0.001) and patients treated with AS (*p*= 0.002) were at significant higher risks compared to AS&AQ; no difference was detected for the other treatments.

Discussion
==========

Safety in general and laboratory data in particular are under-reported in malaria, and limited information can be derived from aggregated data meta-analyses. This study obviates some of these shortcomings by collecting and analysing individual data on a substantial number of patients (about 4,500) from RCTs of loose or fixed-dose artesunate-amodiaquine combinations (about 2,000) *vs*single-agent and combination (artemisinin- or non artemisinin-containing) therapies. Studies were identified through a systematic review of the literature conducted in 2008 and contacting investigators who may be willing to contribute their data \[[@B12]\]. A few additional comparative trials for the treatment of acute falciparum malaria in Sub-Saharan Africa \[[@B11],[@B22],[@B23]\] could not be included. Ideally, a database to monitor safety should be established and constantly updated.

In contrast with meta-analysis of aggregated study reports, individual patient data permit analysis of haematologic parameters as both continuous and categorical (e.g. using common toxicity grades) variables, as well as multivariate analyses including covariates such as individuals, study site, age, baseline parasitaemia, treatment outcome, and treatment group. As a result, conclusions can be drawn as to the contributions to haematologic changes (both toxicity and recovery) of either components of the combination (artesunate and amodiaquine) both individually and together.

Overall, there appears to be no obvious, specific haematologic risk systematically associated with artesunate-amodiaquine as compared to single-agent and other combination (with or without an artemisinin) therapies.

Knowledge of the haematologic changes occurring during acute malaria and recovery is incomplete, limiting our ability to analyse and understand drug-induced changes. A recent analysis from this group of data in African children under five years of age treated for *P. falciparum*\[[@B24]\] showed that acute malaria (pre-treatment) induced a moderate increase in white cells counts (WCC, +5%) resulting from an increase in neutrophils (+43%) that was proportionally larger than the decrease in lymphocytes counts (-16%); haemoglobin and platelets decreased (-13% and -49%). Post-treatment, although there was a small decrease in WCC, the risks of leucopaenia decreased while the risk of neutropaenia increased.

Differently from the above-cited study, the present one had patients of all ages (although 72% were under 5 years old) and no lymphocyte counts. Six of the seven trials of this analysis are in common with the previous analysis \[[@B24]\]. Burkina Faso \[[@B6]\] was not included here since the trial compared two ASAQ combinations, and a study conducted in Rwanda comparing AS+AQ to AQ was added \[[@B17]\]. However, as the present analysis was not restricted to children under five years of age, only around half (54%, 2447/4502) of the patients were in common in both analyses.

In the present study including also about one-third of adults, acute malaria (pre-treatment) was associated with a very low risk of leucopaenia (3%) and neutropaenia (6%); instead, anaemia (about 60%) and thrombocytopaenia (about one-third) were common. Also, older patients were at lower risk for leucopaenia, neutropaenia, anaemia, and thrombocytopaenia, contrary to findings in the narrower group of children under five years of age, for whom no age-effect was apparent except for anaemia \[[@B24]\].

Post-treatment, the risk of leucopaenia, anaemia and thrombocytopaenia decreased, while the risk of neutropaenia increased over time. When interpreting this finding, it should be noted that: (i) the risk post-treatment includes the prevalence of all the events occurring throughout the 28-day follow-up period and (ii) the time trends (analysed as a continuous variable in days) are minimal in particular for leucopaenia and neutropaenia. The respective adjusted risk (AOR) 95%CIs were 0.94-0.98 and 1.02-1.04.

WCC and leucopaenia
-------------------

Leucopaenia was infrequent both at baseline and post-treatment. White blood cells total counts without differential counts appear to be uninformative as they will not capture larger variations in neutrophil counts that are partly compensated by opposite variations in lymphocytes (not assessed here, but seen in under five years old \[[@B24]\]). Baseline WCC counts were overall within the normal ranges but conditions may vary; in one site (Rukara, Rwanda) 30% of patients had leucopaenia pre-treatment \[[@B15],[@B17]\]. Post-treatment, WCC values decreased minimally or remained constant and within normal ranges resulting in a low frequency of leucopaenia (2%) occurring during follow-up, without significant differences between treatments. Older patients were at lower risk, while higher baseline parasitaemia increased the risk. WCC was not a good surrogate for neutropaenia.

Neutrophil counts and neutropaenia
----------------------------------

Baseline neutrophil counts were overall normal (6% neutropaenia, consistent with 7% found in under five years old \[[@B24]\]), but with wide variations across sites (30% in Rukara, Rwanda \[[@B15]\]). There were fewer patients with differential counts recorded post-treatment than patients with total WCC (73% and 86% on Days 14, and 28, respectively). Neutropaenia post-treatment was more frequent than leucopaenia. No significant difference in neutrophil counts was apparent between treatments except for a greater drop (approximately by one-third) by Day 14 with AS&AQ than with artemether-lumefantrine on Day 14, but Day 28 counts were not different.

Age appeared to protect against neutropaenia (here like in \[[@B24]\]), but here there was no association between neutropaenia and baseline parasitaemia or type of treatment (while in under five years old the risk of neutropaenia was lower in case of higher baseline parasitaemia and ACT treatment).

Haemoglobin and anaemia
-----------------------

Anaemia was frequent before treatment (around 60%, on average, and up to 90% in Cameroon and Uganda-Kampala) \[[@B14],[@B16]\] and decreased significantly over time after treatment in all groups. The net gain in haemoglobin by Day 28 was consistently around 10% over the baseline value with most of the treatments. Only artesunate mono-therapy \[[@B13]\] and dihydroartemisinin-piperaquine by Day 14 \[[@B15]\] had a significantly lower gain than with AS&AQ. With all treatments, patients with high parasitaemia and parasitological reappearance during the follow-up were at higher risk of anaemia, while older age protected against anaemia irrespective of the parasitaemia (only the latter found in under five years old \[[@B24]\]).

Artemisinin compounds have been shown to induce reticulocytopaenia both in experimental and clinical conditions potentially by suppressing erythroblasts and that malaria itself could protect against reticulocytopaenia \[[@B25]\]. None of these studies reported reticulocyte counts, and only three studies had a comparator without artesunate (two *vs*amodiaquine alone and one *vs*amodiaquine plus SP). No clear indication results from these studies. In two studies \[[@B5],[@B17]\] the proportion of patients recovering from anaemia by Day 28 was higher after treatment with amodiaquine alone than when combined with artesunate while the proportions of patients becoming anaemic was not different; conversely, no differences were seen between treatments combining amodiaquine with artesunate or SP.

Platelets and thrombocytopaenia
-------------------------------

Only two studies recorded platelets in Mali \[[@B13]\] and in Uganda \[[@B14]\], so it is difficult to generalize. The prevalence of thrombocytopaenia decreased post-treatment (from 32% pre-treatment to 9% on Day 14). A reduction of the risk was observed up to Day 14 corresponding with the upward trend in platelets counts observed in \[[@B24]\]. Baseline parasitaemia did not affect platelets variations, but parasitological reappearance did, and there was a treatment effect in both datasets. A smaller increase in platelets corresponding to a greater risk of thrombocytopaenia was observed in Uganda with AQ+SP (*p*= 0.040) and AL (*p*= 0.013) compared to the AS&AQ, while no difference between groups was detected in Mali.

Adverse events and treatment-related adverse events
---------------------------------------------------

Deviation of laboratory values from normality is graded according to widely accepted severity criteria \[[@B23]\]; however, establishing causality (drug-event relationship) is often a challenge for physicians. The incidence of TEAEs was calculated in the subgroup of patients with values on both Day 0 and post-treatment follow-up through Day 28 (only Day 14 was available for platelets) and found no difference between treatments for neutropaenia, and thrombocytopaenic but a higher risk of TEAEs for anaemia with ACT than with non-artemisinin combinations. TEAEs express more reliably the deterioration of conditions as they exclude AEs, which occurred already at the same intensity before treatment. This analysis was also conservative, as all events, occurring at any time post-treatment, were counted, irrespective of whether the parameter improved later on.

The size of this database (relatively large), the spectrum representation (locations and ages) and the analyses done (multivariate) are all positive features and advantages over single-site papers or meta-analyses of aggregate data. However, a note of caution is needed as to how to interpret these results. The absence of a signal does not mean that there is no risk, or certainty about no excess risk (over other treatments). Rare events will require a very large sample size that was not available here. The sample size is further reduced for individual variables (in particular white blood cells differential counts, hence neutropaenia); also, all variables were not assessed uniformly at the same time. There is also the issue of special risk groups, such as HIV-coinfected subjects (high risk for neutropaenia \[[@B7],[@B8]\]) and pregnant women (potential risk for reticulocytopaenia - reviewed in \[[@B25]\]), which are not represented in the population under study here.
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